Wong Yu Jun, Kumar Rahul, Chua Yu Jing Jonathan, Ang Tiing Leong
Department ofGastroenterology and Hepatology, Changi General Hospital, Singapore 529889, Singapore.
Department of Internal Medicine, Yong Loo Lin School of Medicine, Singapore 117597, Singapore.
World J Hepatol. 2021 Apr 27;13(4):421-432. doi: 10.4254/wjh.v13.i4.421.
Decompensated cirrhosis is characterized by chronic inflammation and severe portal hypertension leading to systemic circulatory dysfunction. Albumin infusion has been widely used in decompensated cirrhosis in patients with spontaneous bacterial peritonitis, large-volume paracentesis and hepatorenal syndrome. Emerging data suggest long-term albumin infusion has both oncotic and non-oncotic properties which may improve the clinical outcomes in decompensated cirrhosis patients. We review the current literature on both the established and potential role of albumin, and specifically address the controversies of long-term albumin infusion in decompensated cirrhosis patients.
失代偿期肝硬化的特征是慢性炎症和严重门静脉高压,导致全身循环功能障碍。白蛋白输注已广泛应用于失代偿期肝硬化合并自发性细菌性腹膜炎、大量腹腔穿刺放液及肝肾综合征的患者。新出现的数据表明,长期白蛋白输注具有胶体渗透压和非胶体渗透压特性,可能改善失代偿期肝硬化患者的临床结局。我们综述了关于白蛋白既定作用和潜在作用的当前文献,并特别讨论了失代偿期肝硬化患者长期白蛋白输注的争议。